Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Future Medical Device Companies -- Ignore unavailable to you. Want to Upgrade?

To: dr.praveen who wrote (63)	3/2/2007 1:34:49 AM
From: dr.praveen	Read Replies (1) \| Respond to of 136

Stereotaxis Initiates HEAL HF Clinical Trial Thursday March 1, 3:27 pm ET First magnetic case to evaluate the ability to optimize Cardiac Resynchronization Therapy (CRT) using Niobe Magnetic Navigation System enrolled in San Raffaele University Hospital Milan, Italy ST. LOUIS, March 1 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS - News) announced today that it has initiated the HEAL HF clinical trial, which is designed to evaluate the ability to magnetically navigate to multiple potential pacing sites and then optimize LV lead placement to treat heart failure. Professor Carlo Pappone M.D., Ph.D. is the first investigator to successfully enroll patients in the HEAL HF study. This international study is being conducted at five centers in Europe, Canada and the United States. The case included the evaluation of seven pacing sites in the left ventricle, which exhibited significant differences from site-to-site in the hemodynamic response of the patient's heart, measuring cardiac function. The Stereotaxis system makes it feasible to quickly search for the optimal position by affording access to difficult to reach locations. The system stores previously accessed sites, providing physicians the capability and confidence that they will be able to return to the site that yields the greatest physiological response. Bevil Hogg, CEO of Stereotaxis, stated, "Historically, up to 30 percent of heart failure patients do not improve after CRT implantation. We are very excited to be working with Medtronic, Inc. on this study, and we believe that our technology has the potential to improve patient response rates by optimizing lead placement." "Stereotaxis gives the physician the ability to interrogate multiple vascular locations, potentially maximizing the benefit patients receive from their implantable device," said Professor Pappone.